Aplidine treatment of cancers
CA 2391502 A1 · Owner: Paz-Ares, Luis · Inventors: Twelves, Chris; Paz-Ares, Luis; Faircloth, Glynn Thomas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Aplidine demonstrates considerable promise in phase (I) clinical trials for treatment of tumours, and various dosing regimes are given. Tumor reduction has been observed in several tumour types including renal carcinoma colorectal cancer, lung carcinoid, medullary thyroid carcinomas and melanoma. It has also been found that aplidine has a role in inhibiting angiogenesis complementing the anti-tumour activity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 15, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 15, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 15, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.